Testing cosmetics for skin compatibility

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the skin compatibility of cosmetic products, both new and reformulated, by conducting dermatological patch tests. These tests are essential for identifying potential irritants and allergens in cosmetics that could cause dermatitis or allergic reactions. Participants will undergo patch testing to assess their skin's reaction to various cosmetic substances. The goal is to enhance safety and reduce adverse skin reactions associated with cosmetic use.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Men and women older than 18 years old
* Persons undergoing a diagnostic patch test for reason of a skin disease
* Signed written informed consent

Exclusion Criteria:

* Acute skin inflammation and eczema on the back
* Systemic corticosteroid and immunosuppressive therapy as well as UV exposure of the back within the last 4 weeks
* Topical corticosteroids used on the back within the last two weeks

Where it's running

• Inselspital Bern
  Bern, Switzerland Recruiting

Study contacts

• Principal investigator: Dagmar Simon, MD — Dept. of Dermatology, Inselspital
• Study coordinator: Dagmar Simon, MD
• Email: dagmar.simon@insel.ch
• Phone: +41 31 632 2278

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Camoteskimab in adults with moderate-to-severe atopic dermatitis

  This trial tests different doses of camoteskimab versus placebo to see if it helps adults with moderate-to-severe atopic dermatitis who have not fully responded to standard treatments.

  Recruiting at 31 sites Phase 2 Apollo Therapeutics Ltd · Birmingham, Alabama and 84 other locations · NCT07599813

• Single subcutaneous dose of SHR-1894 in healthy adults

  This trial will test a single under-the-skin (subcutaneous) dose of SHR-1894 in healthy adults to see if it is safe and how the body processes it.

  Recruiting Phase 1 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Chengdu, Sichuan · NCT07414602

• Post-marketing follow-up of 047 TD Dermatitis Cream for adults and children with atopic or contact dermatitis

  This will try 047 TD Dermatitis cream twice a day for 28 days to see if it reduces severity and symptoms in children and adults with atopic or contact dermatitis.

  Recruiting Biokosmes Srl · Milan and 2 other locations · NCT07056569

• Post-market follow-up of ChitoCare® Medical for scars, post-dermatological care, dermatitis, and acne

  This project will try ChitoCare® Medical gel and spray to see if they are safe and help heal scars, skin after dermatologic procedures, dermatitis, and acne in people who use them.

  Recruiting at 2 sites Primex ehf · Prague and 1 other locations · NCT06850389

• Investigating how eczema treatments affect skin bacteria

  This study is testing how different eczema treatments affect the skin bacteria in people with moderate to severe eczema and healthy volunteers.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT01631617

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.